Global developmental delay with sodium valproate-induced gingival hyperplasia

Patil, Ravi B; Urs, Pallavi; Kiran, Shital; Bargale, Seema

doi:10.1136/bcr-2013-200672

Cited by 6 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reported cases of gingival enlargements were induced by different drugs; CCBs (50/119 – of which amlodipine-25;[8910111213141516171819202122232425262728] nifedipine-13;[26293031323334353637383940] verapamil-4;[41] felodipine-2;[4243] nisoldipine-1;[44] manidipine-1;[45] and unspecified CCBs-4[46]); phenytoin (11/119);[4748495051525354555657] cyclosporine (31/119);[3546585960616263646566676869707172737475] phenobarbital (4/119);[767778] sodium valproate (3/119 - including one report of congenital drug-induced gingival hyperplasia);[798081] d-penicillamine (2/119);[82] combination oral contraceptive pill-lynestrenol and ethinyl estradiol (1/119);[83] vigabatrin (1/119). [84] Cases of gingival enlargement after combination drug therapy have also been reported; a combination of cyclosporine and CCBs (11/119);[354685...…”

Section: Resultsmentioning

confidence: 99%

Drug-induced gingival overgrowth: A critical insight into case reports from over two decades

Samudrala

Chava

Chandana

et al. 2016

J Indian Soc Periodontol

View full text Add to dashboard Cite

Drug-induced gingival overgrowth (DIGO) is a well-recognized adverse effect of certain systemic medications. Calcium channel blockers, anticonvulsants, and immunosuppressants are frequently implicated drugs in the etiology of DIGO. Drug variables, plaque-induced inflammation, and genetic factors are the three important factors in the expression of gingival changes after systemic medication use. Careful clinical examination and thorough history taking form the basis for diagnosis of DIGO. Histopathological examination is often neglected; however, it is an important aid that helps in differential diagnosis. Cessation or change of drug and meticulous plaque control often leads to regression of the lesion, which however might need surgical correction for optimal maintenance of gingival health. The purpose of the present article is to review case reports and case series published in the last two decades and to assimilate and compile the information for clinical applications such as diagnosis and therapeutic management of DIGO.

show abstract

Section: Resultsmentioning

confidence: 99%

Drug-induced gingival overgrowth: A critical insight into case reports from over two decades

Samudrala

Chava

Chandana

et al. 2016

J Indian Soc Periodontol

View full text Add to dashboard Cite

show abstract

“…In a general way the pathogenesis of drug-influenced gingival enlargement can be considered in a multifactorial way involving an interaction of several factors such as drug metabolism with gingival fibroblasts, age, genetic predisposition and even inflammatory changes (13) . In this respect, the new classification of periodontal diseases exemplifies the importance of bacterial biofilm as one of the essential factors for drug-influenced gingival enlargement, however without specifying this relationship with valproic acid derivatives (1) .…”

Section: Discussionmentioning

confidence: 99%

Non-surgical periodontal treatment for drug-influenced gingival enlargement: a four-year follow-up case report

Silva

Hisse-Gomes

Cruz

et al. 2021

Int. j interdiscip. dent.

View full text Add to dashboard Cite

Drug-influenced gingival enlargement is considered to be an important side effect related to the use of some medications and often produces important esthetic changes for patients, as well as clinical symptoms such as pain, bleeding, abnormal tooth movement and occlusion problems. Anticonvulsants, immunosuppressants and antihypertensive drugs have been reported as the main inducers of these periodontal disorders. This case report describes the 4-year clinical follow-up of a young patient with a history of excessive gingival enlargement as a consequence of drug therapy for epilepsy (phenytoin and phenobarbital); the nonsurgical periodontal treatment of the excessive gingival enlargement was associated with the replacement of the patient's epilepsy medications with valproic acid. We conclude that intensive mechanical control of bacterial biofilms, instruction on oral hygiene guidelines and behaviors and the substitution of alternative anticonvulsant medications are the best way to control the drug-influenced gingival enlargement..

show abstract

“…in 2014 reported a case of sodium valproate induced gingival enlargement in a 5 year old child in association with Gobal developmental delay. [ 10 ]…”

Section: Discussionmentioning

confidence: 99%

Sodium valproate induced gingival enlargement in 22 months old child

Chandulal

Ganatra

2014

J Indian Soc Periodontol

View full text Add to dashboard Cite

Gingival enlargement is a common clinical feature seen in patients suffering from gingival and periodontal diseases and is a common side-effect of drugs such as anti-convulsants, calcium channel blockers and immunosuppresants. This is a case report of 22 months old child suffering from gingival enlargement following intake of sodium valproate. Among the anti-convulsants phenytoin is commonly associated with gingival enlargement; however, there are not many cases reported on sodium valproate induced gingival enlargement.

show abstract

Global developmental delay with sodium valproate-induced gingival hyperplasia

Cited by 6 publications

References 5 publications

Drug-induced gingival overgrowth: A critical insight into case reports from over two decades

Drug-induced gingival overgrowth: A critical insight into case reports from over two decades

Non-surgical periodontal treatment for drug-influenced gingival enlargement: a four-year follow-up case report

Sodium valproate induced gingival enlargement in 22 months old child

Contact Info

Product

Resources

About